Clinical medicine profile
Reserpine/Clopamide/ Dihydroergocristine
Therapeutic agent (verify pharmacological class)
- Route
- See product SmPC
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Sulphonamide sensitivity
- persistent hypokalaemia
- depression
- acute gas- tric/duodenal ulcer
- pregnancy
- lactation
- ulcerative colitis
- direct acting sympathomimetics.
Precautions
- Impaired hepatic and/or renal func- tions
- diabetes
- monitored serum potassium and uric acid levels
- epilepsy
- concurrent admin- istration with levodopa
- cardiac infarction
- cardiac damage.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
1 tab OD, can be increased after one week by 1 tab [max 3 tabs daily]. Maintenance dose: 1 tab OD.
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Review renal impairment dosing; many agents need CrCl/eGFR adjustment.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.
Use, effects & interactions
Indications
- Essential hypertension
- arterial and renal hypertension.
- Clinical selection for Reserpine/Clopamide/ Dihydroergocristine should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
- Class context: Therapeutic agent (verify pharmacological class).
- Confirm site-specific dose, duration and monitoring before prescribing.
Adverse effects
- Postural hypotension
- blood dyscra- sia
- headache
- GI disturbances
- flushing
- depression
- suicidal tendency
- nasal congestion
- glycosuria in diabetes
- muscle spasm
- dry mouth
- parkinson-like syndrome
- increased appetite
- loss of libido.
Drug interactions
Open multi-drug checker ↗- Drug interactions:Rifampacin
- hyperglycaemic agents
- diltiazem
- beta-adrenergic agonists.
- Fixed-dose/multi-ingredient product.
- Clinical details partially inherited from component monographs: Reserpine/Clopamide/ Dihydroergocristine.
- Confirm combination SmPC for exact dosing.
Mechanism & disposition
Reserpine is a pure crystal- line alkaloid of Rauwolfia.
Read complete mechanism
Reserpine is a pure crystal- line alkaloid of Rauwolfia. Reserpine acts by depleting stores of catecholamines and 5- hydroxytryptamine in many organs, resulting in a decreased heart rate and a lowering of arterial blood pressure. Clopamide is a thiazide diuretic. Dihydroergocristine is dihydrogenated ergot alkaloids whose mechanism of action is not fully understood. It is thought to act centrally to decrease vascular tone and slows the heart rate, and acts peripherally to block alpha-receptors.
Product-specific
Product-specific
See product SmPC
are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Pregnancy, lactation & diet
[Reserpine] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist. [Clopamide] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist. [Dihydroergocristine] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
[Reserpine] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data. [Clopamide] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data. [Dihydroergocristine] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| No reviewed brand listings are linked yet. | |||
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.